Krajina: Nový Zéland
Jazyk: angličtina
Zdroj: Medsafe (Medicines Safety Authority)
Neisseria meningitidis Group A polysaccharide 50ug; Neisseria meningitidis Group C polysaccharide 50ug; Neisseria meningitidis Group W135 polysaccharide 50ug; Neisseria meningitidis Group Y polysaccharide 50ug
sanofi-aventis new zealand limited
Neisseria meningitidis Group A polysaccharide 50 µg
0.5 mL
Injection with diluent
Active: Neisseria meningitidis Group A polysaccharide 50ug Neisseria meningitidis Group C polysaccharide 50ug Neisseria meningitidis Group W135 polysaccharide 50ug Neisseria meningitidis Group Y polysaccharide 50ug Excipient: Lactose monohydrate Sodium chloride Purified water
Combination pack, 1 x ( powder + diluent ), 1 dose unit
Prescription
Prescription
Sanofi Pasteur Inc
Menomune® ACYW-135 is indicated for active immunisation of adults and children older than 2 years against disease caused by Neisseria meningitidis Groups A, C, Y and W-135, the major manifestation being meningococcal meningitis. Vaccination may be considered for the following individuals: · Travellers to countries recognised as having highly endemic or epidemic disease. · Control of epidemics of infection caused by Neisseria meningitidis groups A, C, Y and W-135 in confined communities. · Individuals at particular high risk of acquiring meningococcal infection, including persons with anatomic or functional asplenia. · Close contacts of persons with meningococcal disease due to groups A, C, Y and W-135, as an adjunct to appropriate chemoprophylaxis.
Package - Contents - Shelf Life: Combination pack, 1 x ( powder + diluent ) - 1 dose units - 24 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze) protect from light - Vial, diluent - 0.6 mL - 60 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze) - Vial, 1 x monodose powder - 1 dose units - 24 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze)
1987-04-02
MENOMUNE ® 1 MENOMUNE ® – A/C/Y/W-135 _Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Menomune vaccine. It does not contain all available information. It does not take the place of talking to your doctor or pharmacist. All medicines, including vaccines, have risks and benefits. Your doctor has weighed the risks of you having Menomune vaccine against the benefits your doctor expects it will have. If you have any concerns about this vaccine, ask your doctor, nurse or pharmacist. KEEP THIS LEAFLET. YOU MAY NEED TO READ IT AGAIN. WHAT MENOMUNE VACCINE IS USED FOR Menomune vaccine is used to help prevent meningitis or infections caused by the meningococcal bacteria groups A, C, Y and W-135. Menomune vaccine is used to help prevent meningitis in people likely to be infected with the meningococcal bacteria. These include: travellers to countries where there is a risk of contracting meningitis people living in an area where an outbreak or epidemic of meningitis has occurred people in close contact with someone who has meningitis people at high-risk of contracting meningitis such as those who have their spleen removed or those whose spleen does not work properly HOW MENOMUNE VACCINE WORKS Menomune vaccine works by causing your body to produce its own protection against infections caused by meningococcal bacteria groups A, C, Y and W-135. It does this by making substances called antibodies in the blood which fight meningococcal bacteria. If a vaccinated person comes into contact with meningococcal bacteria groups A, C, Y and W-135, the body is usually ready to destroy it. Your body usually takes several weeks after vaccination to develop protection against the meningococcal bacteria. Protection requires one dose. Most people will produce enough antibodies against meningococcal bacteria groups A, C, Y and W-135. However, as with all vaccines, 100% protection cannot Prečítajte si celý dokument
MENOMUNE DATA SHEET Supercedes version dated: Nov 2007 Last revised: 7 June 2013 MENOMUNE ® ACYW-135 _MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP A, GROUP C, GROUP Y AND _ _GROUP W-135 _ DESCRIPTION The vaccine is a freeze-dried preparation of the group specific antigens from _Neisseria _ _meningitidis_, serogroups A, C, Y and W-135. When reconstituted, the vaccine is a clear colourless liquid. After reconstitution with the accompanying diluent, each 0.5 mL dose of vaccine contains: ACTIVE INGREDIENTS: Meningococcal polysaccharide Group A 50 µg/dose Meningococcal polysaccharide Group C 50 µg/dose Meningococcal polysaccharide Group Y 50 µg/dose Meningococcal polysaccharide Group W-135 50 µg/dose EXCIPIENTS: Lactose 2.5 mg to 5.0 mg/dose Sodium chloride 4.25 to 4.75 mg/dose Water for injection No preservative is added. The manufacture of this product includes exposure to bovine derived materials. No evidence exists that any case of vCJD (variant Creutzfeldt-Jakob disease, considered to be the human form of bovine spongiform encephalopathy) has resulted from the administration of any vaccine product. USES _PHARMACOLOGY _ Vaccination with the meningococcal polysaccharides induces the production of bactericidal antibodies which are group specific. That is, the group A polysaccharide induces antibodies only against Group A, and not against any other serogroups. Antibody responses to each component of Menomune ® ACYW-135 have been similar to the responses of the individual polysaccharides administered alone. A study using 4 lots of Menomune ® ACYW-135 in 150 adults showed at least a four-fold increase in bacterial antibodies to all four antigen serogroups in greater than 90% of Prečítajte si celý dokument